Voluntary Medical Device Corrections (MDCs) Impact
Two voluntary MDCs for cannula tear issues resulted in a $29.3 million net charge in Q2, with total estimated costs of $60–70 million expected through 2027.
INSULET CORP is expected to release its Q3 2026 10-Q filing in the upcoming earnings season. Last quarter: Insulet delivered strong revenue growth and a net income surge in Q2 FY2026, driven by Omnipod 5 demand, though rising costs and product correction charges pressured margins.
Drawn from management commentary in the Q2 2026 10-Q:
Two voluntary MDCs for cannula tear issues resulted in a $29.3 million net charge in Q2, with total estimated costs of $60–70 million expected through 2027.
Omnipod 5 launched in Spain and the Middle East; U.S. rollout of algorithm enhancements including a lower 100mg/dL target glucose set point and integration with Abbott's Freestyle Libre 3 Plus sensor.
SG&A expenses increased 33.8% due to headcount additions, market development investments, and the prior-year reversal of stock-based compensation from the former CEO's departure amplifying the comparison.
Revenue
$801.7M
+23.51% YoY
EPS (Diluted)
$1.37
+328.13% YoY
Gross Margin
70.2%
+0.5 pts YoY
Operating Income
$129.7M
+7.10% YoY
Add PODD to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.